Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Introduction Neuropathic pain is a persistent pain condition caused by nerve damage or dysfunction in the nervous system. It is distinct from n ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The spot makes lofty claims about weight-loss drugs offered by the telehealth company Hims & Hers, but says little about ...
6d
Glazer has been diagnosed with anxiety, depression, ADHD and bipolar disorder. His mental health playbook includes frequent ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) rose 5% Tuesday morning on news the FDA has approved its wearable treatment device Onapgo, formerly known as SPN-830, for the treatment of patients ...
View Supernus Pharmaceuticals, Inc. (SUPN) current and estimated P/E ratio data provided by Seeking Alpha.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Set to release on February 28, 2025, Dabba Cartel is a gripping crime thriller on Netflix that tells the story of five women whose small food business inadvertently transforms into a high-stakes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback